Natco Pharma Limited

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Request demo

Natco Pharma Limited - overview

About

Natco Pharma Limited is a pharmaceutical company focused on developing, manufacturing, and marketing a diverse range of high-quality drugs, particularly in oncology and other therapeutic areas, catering to global healthcare markets. Founded in 1981 and headquartered in Hyderabad, India, Natco Pharma Limited specializes in pharmaceutical products and has established a notable presence in oncology. The company has evolved its business strategy over the years, including its expansion into agrochemicals through its Crop Health Sciences division. Rajeev Nannapaneni serves as the CEO.

Natco has raised a total of INR 1,110. 00 mn in funding, with the latest funding round being a Private Placement/Follow on completed on June 28, 2017. Natco Pharma Limited specializes in a diversified range of pharmaceutical products with a strong emphasis on oncology, where it has established a solid brand presence. The company’s specialty division encompasses therapy segments such as Gastroenterology/Hepatology, Orthopedic/Rheumatology, Neurology, and Infectious Diseases, including HIV, providing trusted solutions for cardiovascular care and diabetes management.

Its Active Pharmaceutical Ingredients (APIs) focus on complex and difficult-to-manufacture molecules, particularly in the oncology segment, catering to a global clientele of healthcare providers and pharmaceutical companies. In addition to pharmaceuticals, Natco has expanded its operations into agrochemicals through its Crop Health Sciences division, producing high-quality crop protection formulations aimed at farmers worldwide. The firm operates in various international markets, ensuring a broad reach for its products and services, including regions in North America, Europe, and Asia. Natco Pharma Limited reported a revenue of INR 483,057,006.

6 for the fiscal year 2024, with an EBITDA of INR 214,843,674. 7. The company primarily operates through a B2B model, selling its pharmaceutical and agrochemical products to healthcare institutions, wholesalers, and retail pharmacies. Natco's flagship products are positioned to address specific therapeutic needs, contributing significantly to its revenue generation strategy.

Natco Pharma Limited plans to leverage its recent funding of INR 1,110. 00 mn to enhance its product development initiatives, particularly focusing on new oncology drugs designed for release in the coming years. The company aims to expand its market presence in North America and Europe by 2025, targeting healthcare partnerships and distribution channels to support this growth. Continuous investment in innovative product lines and geographic expansion will be key components of Natco's growth strategy moving forward.

Current Investors

Multiples Alternate Asset Management, Kotak Alternate Asset Managers, ICICI Prudential Asset Management Company Ltd

Request a demo

Primary Industry

Pharmaceuticals

Sub Industries

Pharmaceutical Research & Development, Biomaterials

Website

www.natcopharma.co.in

Verticals

Manufacturing

Company Stage

Mature

Total Amount Raised

Subscriber access only

Natco Pharma Limited - financials

Fiscal Year Ended	Mar 31, 2012	Mar 31, 2013	Mar 31, 2014	Mar 31, 2015	Mar 31, 2016	Mar 31, 2017	Mar 31, 2018	Mar 31, 2019	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024
Revenue (USD)	5,200,463,610	6,605,259,670	7,388,925,493	8,252,760,441	11,416,163,111	20,650,000,000	22,020,000,000	20,945,000,000	19,150,000,000	20,521,000,000	-	-	-
% Revenue Growth (YoY)	-	27.0%	11.9%	11.7%	38.3%	80.9%	6.6%	(4.9%)	(8.6%)	7.2%	-	-	-
EBITDA (USD)	1,159,982,606	1,483,973,898	1,954,776,633	2,126,059,760	2,751,788,997	6,892,000,000	9,439,000,000	8,352,000,000	6,109,000,000	6,532,000,000	-	-	-
Operating Income (USD)	1,000,903,691	1,262,751,308	1,650,342,641	1,653,403,215	2,242,263,594	6,348,000,000	8,777,000,000	7,542,000,000	5,111,000,000	5,363,000,000	-	-	-
Operating Margin	19.2%	19.1%	22.3%	20.0%	19.6%	30.7%	39.9%	36.0%	26.7%	26.1%	-	-	-
% EBITDA Margin	22.3%	22.5%	26.5%	25.8%	24.1%	33.4%	42.9%	39.9%	31.9%	31.8%	-	-	-
NET Income (USD)	596,083,458	718,690,784	1,027,342,878	1,346,157,749	1,551,754,190	4,849,000,000	6,952,000,000	6,424,000,000	4,581,000,000	4,424,000,000	-	-	-
% Net Margin	11.5%	10.9%	13.9%	16.3%	13.6%	23.5%	31.6%	30.7%	23.9%	21.6%	-	-	-

Natco Pharma Limited - deals

Deals Type	Deal Status	Target (s)	Deal Date
Add-on, Corporate Carve Out	Completed	PT Natco Lotus Farma	-
Add-on, Public to Private	Announced	Adcock Ingram Holdings	-
Add-on	Completed	Veda Seed Sciences Pvt. Ltd.	-
Private Placement/Follow on	Completed	Natco Pharma Limited	-
PIPE	Completed	Natco Pharma Limited	-

Displaying 1 - 5 of 11

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.

Request demo